» Articles » PMID: 4717022

Effects of Enzyme Inhibitors of Catecholamine Metabolism and of Haloperidol on the Pancreatic Secretion Induced by L-DOPA and by Dopamine in Dogs

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 1973 Jan 1
PMID 4717022
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

1. Effects of inhibitors of DOPA decarboxylase, dopamine beta-hydroxylase and monoamine oxidase, and haloperiodol on the secretion of pancreatic juice induced by L-DOPA and dopamine were studied in preparations of the isolated blood-perfused canine pancreas.2. The increased secretion induced by the infusion of L-DOPA (100 mug/min) was completely antagonized by Ro 4-4602 (300 mug), a DOPA decarboxylase inhibitor.3. The secretogogue effect of dopamine (1-10 mug) intra-arterially was not affected by Ro 4-4602, but was enhanced by the infusion of fusaric acid (100 mug/min), a dopamine beta-hydroxylase inhibitor.4. The increase in the secretion induced by dopamine (1-10 mug) was enhanced by treatment with nialamide (100 mg/kg), a monoamine oxidase inhibitor, given intravenously.5. Haloperidol (1 mg) intra-arterially attenuated the dopamine-induced pancreatic secretion.6. It is concluded that L-DOPA is converted to dopamine in the acinar cells which causes an increase in the secretion of pancreatic juice, thus the intracellular level of dopamine may be controlled by enzymatic equilibrium.

Citing Articles

Evaluating the effects and safety of intravenous lipid emulsion on haloperidol-induced neurotoxicity in rabbit.

Moshiri M, Mohammadpour A, Vahabzadeh M, Etemad L, Memar B, Hosseinzadeh H Biomed Res Int. 2014; 2014:949262.

PMID: 24971362 PMC: 4058127. DOI: 10.1155/2014/949262.


Modification by drugs of the secretagogue effect of dopamine on the pancrease.

Furuta Y, Hashimoto K, Ishii Y, Iwatsuki K Br J Pharmacol. 1974; 51(2):225-30.

PMID: 4615760 PMC: 1776740. DOI: 10.1111/j.1476-5381.1974.tb09651.x.


Action of dopamine on the exocrine pancreatic secretion of the intact dog.

Delcenserie R, Devaux M, SARLES H Br J Pharmacol. 1986; 88(1):189-95.

PMID: 2871881 PMC: 1917094. DOI: 10.1111/j.1476-5381.1986.tb09486.x.


The effects of some gastrointestinal hormones and metoclopramide on cardiovascular dopamine receptors [proceedings].

Blower P, Flack J, DAY M Br J Pharmacol. 1977; 61(1):124P-125P.

PMID: 912177 PMC: 1667637.


Haloperidol, a dopaminergic antagonist: somatostatin-like inhibition of glucagon and insulin release from the isolated, perfused canine pancreas.

Hermansen K Diabetologia. 1978; 15(4):343-7.

PMID: 710756 DOI: 10.1007/BF03161000.


References
1.
Petkov P . [Monoamine oxidasic activity in the pancreas of man and certain mammals: white rat, guinea pig, cat and rabbit]. Ann Histochim. 1965; 10(1):17-24. View

2.
Hornykiewicz O . Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966; 18(2):925-64. View

3.
SYMCHOWICZ S, Korduba C, Veals J, TABACHNICK I . Norepinephrine biosynthesis in the rat pancreas. Biochem Pharmacol. 1968; 17(11):2313-7. DOI: 10.1016/0006-2952(68)90039-7. View

4.
Brooks H, Stein P, Matson J, HYLAND J . Dopamine-induced alterations in coronary hemodynamics in dogs. Circ Res. 1969; 24(5):699-704. DOI: 10.1161/01.res.24.5.699. View

5.
Yeh B, MCNAY J, Goldberg L . Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: evidence for a specific dopamine receptor. J Pharmacol Exp Ther. 1969; 168(2):303-9. View